Bristol-Myers Squibb Co. (BMY) Tops Q3 EPS by 3c; Narrows FY11 Guidance
Bristol-Myers Squibb Co. (NYSE: BMY) reported Q3 EPS of $0.61, $0.03 better than the analyst estimate of $0.58. Revenue for the quarter came in at $5.3 billion versus the consensus estimate of $5.3 billion.
Bristol-Myers Squibb Co. sees FY2011 EPS of $2.25-$2.30, versus prior guidance of $2.20-$2.30 and the consensus of $2.8.
Bristol-Myers Squibb Co. sees FY2011 EPS of $2.25-$2.30, versus prior guidance of $2.20-$2.30 and the consensus of $2.8.